Potential role of abciximab in ischemic cerebrovascular disease.

Abstract

Abciximab is an intravenously administered antiplatelet agent that could be used alone or in conjunction with thrombolytic therapy to treat patients with acute ischemic stroke. However, experience with medication for treatment of patients with stroke is limited. Symptomatic intracranial bleeding is the most common serious complication of therapies that aim at restoring or improving blood flow to the brain after stroke and it is the most likely potential serious complication of the use of abciximab in this setting. Preliminary data suggest that abciximab is not associated with a prohibitively high rate of symptomatic intracranial hemorrhage. Further research is needed to determine the safety and potential efficacy of abciximab for treatment of ischemic stroke.

• Authors: J M Winkley, H P Adams Jr
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 85 Issue 8A Pg. 47C-51C (Apr 27 2000) ISSN: 0002-9149 [Print] United States
• PMID: 10793180 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Anticoagulants
• Immunoglobulin Fab Fragments
• Platelet Aggregation Inhibitors
• Streptokinase
• Abciximab

Topics

• Abciximab
• Antibodies, Monoclonal (therapeutic use)
• Anticoagulants (therapeutic use)
• Brain Ischemia (drug therapy)
• Humans
• Immunoglobulin Fab Fragments (therapeutic use)
• Platelet Aggregation Inhibitors (therapeutic use)
• Streptokinase (therapeutic use)
• Thrombolytic Therapy
• Treatment Outcome